Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia.

@article{Tutor2002LossOH,
  title={Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia.},
  author={Olga Tutor and Miguel Angel D{\'i}az and Manuel Ram{\'i}rez and Patricia Algara and Lu{\'i}s Madero and P Mart{\'i}nez},
  journal={Leukemia research},
  year={2002},
  volume={26 9},
  pages={817-20}
}
We evaluated the incidence of MTS1/p16 deletions by loss of heterozygosity (LOH) analysis in 36 non-high risk B-cell precursor childhood acute lymphoblastic leukemia (BCP-ALL) and correlated these results with clinical features and with the presence of minimal residual disease (MRD) at the end of induction therapy. LOH was analyzed using three microsatellite markers flanking the p16 gene. MRD was studied by the polymerase chain reaction (PCR) for IgH and TCRdelta genes. All patients were… CONTINUE READING